

Special Issue

Treatment of Hepatopancreatobiliary Cancers: Open Question, Challenge, and Future Directions

Message from the Guest Editors

The rates of hepatopancreatobiliary (HPB) malignancies are rising. Surgery is the cornerstone of treatment. However, only marginal improvements in patient survival have been achieved over the past few decades. Anatomical localisation of the tumours in the vicinity of critical vascular structures, disease diffusion (e.g., peritoneal carcinomatosis, oligometastatic disease), and aggressive tumour biology are often responsible for poor outcomes. Recently, more aggressive approaches have been adopted, including extensive vascular resection, neoadjuvant treatments, and locoregional therapies. Liver transplantation (LT) is a well-recognised treatment for hepatocellular carcinoma (HCC) and is increasingly being considered in cholangiocarcinoma and colorectal liver metastases. Minimally invasive and ablative therapies are an adjunct or even replacement for resection. More recently, artificial intelligence in HPB surgery has shown promising implications in diagnosis and targeted treatment. This Special Issue aims to focus on these extended indications and novel therapeutic approaches as they are paramount in improving the prognosis of these detrimental malignancies.

Guest Editors

Dr. Francesco Giovinazzo

General Surgery and Organ Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy

Dr. Stijn van Laarhoven

Department of HPB Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Deadline for manuscript submissions

closed (10 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139628

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)